Valeo Pharma Inc. (VPH.TO)
| Previous Close | 0.1100 |
| Open | 0.1100 |
| Bid | 0.1050 x N/A |
| Ask | 0.1100 x N/A |
| Day's Range | 0.1000 - 0.1100 |
| 52 Week Range | 0.1000 - 0.5200 |
| Volume | |
| Avg. Volume | 43,738 |
| Market Cap | 10.359M |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Steve Saviuk, Valeo's Chief Executive Officer, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
- CNW Group
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has joined the Company's Board of Directors.
- CNW Group
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2024.
